Compositions and methods for selective inhibition of nicotine acetylcholine receptors
申请人:Papke L. Roger
公开号:US20050119309A1
公开(公告)日:2005-06-02
The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro.
本发明涉及通过向患者投与2,2,6,6-四甲基哌啶-4-基庚酸酯(TMPH)或其药学上可接受的盐来治疗或预防以尼古丁乙酰胆碱受体功能障碍为特征的神经系统疾病的方法。在另一个方面,本发明涉及含有TMPH或其药学上可接受的盐和药学上可接受的载体的制药组合物。在另一个方面,本发明涉及通过将有效量的TMPH或其药学上可接受的盐接触到缺乏α5、α6或β3亚基的尼古丁乙酰胆碱受体上来选择性地抑制受体的方法。选择性抑制缺乏α5亚基的尼古丁乙酰胆碱受体的方法可以在体内或体外进行。